These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8938230)

  • 1. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
    Figg WD; Dawson N; Middleman MN; Brawley O; Lush RM; Senderowicz A; Steinberg SH; Tompkins A; Reed E; Sartor O
    Acta Oncol; 1996; 35(6):763-5. PubMed ID: 8938230
    [No Abstract]   [Full Text] [Related]  

  • 2. Response of carcinoma of the prostate to withdrawal of flutamide.
    Collinson MP; Daniel F; Tyrrell CJ; Teasdale C
    Br J Urol; 1993 Nov; 72(5 Pt 1):662-3. PubMed ID: 10071562
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
    Sartor O; Cooper M; Weinberger M; Headlee D; Thibault A; Tompkins A; Steinberg S; Figg WD; Linehan WM; Myers CE
    J Natl Cancer Inst; 1994 Feb; 86(3):222-7. PubMed ID: 7506794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
    Small EJ; Srinivas S
    Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiandrogen withdrawal syndrome in relapsed prostate cancer.
    Scher HI; Kolvenbag GJ
    Eur Urol; 1997; 31 Suppl 2():3-7; discussion 24-7. PubMed ID: 9074903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
    Barqawi A; Akduman B; Abouelfadel Z; Robischon M; Crawford ED
    BJU Int; 2003 Nov; 92(7):695-8. PubMed ID: 14616448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
    Scher HI; Zhang ZF; Nanus D; Kelly WK
    Urology; 1996 Jan; 47(1A Suppl):61-9. PubMed ID: 8560680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent androgen suppression--ready for prime time?
    Ischia J; Goldenberg SL
    J Urol; 2012 Jun; 187(6):1956-7. PubMed ID: 22503023
    [No Abstract]   [Full Text] [Related]  

  • 10. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Zerbib M; Payan C
    Urology; 1996 Oct; 48(4):661-3. PubMed ID: 8886082
    [No Abstract]   [Full Text] [Related]  

  • 12. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Crawford ED
    Urology; 1995 Dec; 46(6):899-901. PubMed ID: 7502440
    [No Abstract]   [Full Text] [Related]  

  • 13. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
    Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM
    South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histological investigation of prostate cancer treated with hormonal agents].
    Azumi M; Saga Y; Hashimoto H; Kakizaki H
    Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
    Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
    Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy.
    Teruel JL; Cano T; Marcén R; Villafruela JJ; Rivera M; Fernández-Juarez G; Ortuño J
    Nephrol Dial Transplant; 1997 Jun; 12(6):1262-3. PubMed ID: 9198065
    [No Abstract]   [Full Text] [Related]  

  • 18. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer.
    Burns-Cox N; Basketter V; Higgins B; Holmes S
    Int J Urol; 2002 Aug; 9(8):431-4. PubMed ID: 12225339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.